Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sonoporation-Enhanced Chemotherapy in Inoperable Pancreatic Cancer
2024-512176-35-00Phase 2Authorised
- Sponsor
- Helse Bergen
- Start
- Sep 2024
- Modality
- Acoustic/Optical: Sonoporation, laser photoporation → Physical Methods → Gene Addition/Replacement → Gene Therapies, Nanoparticles → Drug Delivery Systems
- Countries
- 2
01
Overview
Phase 2 trial of sonazoid in pancreatic adenocarcinoma (PDAC) (2 arms), sponsored by Helse Bergen. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: authorised.
02
Drugs
sonazoid
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on 2024-512176-35-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512176-35-00.